AgingResearch.NewsJoin free

Institut Mérieux

Company

Wikidata

Institut Mérieux develops one asset, in phase 1 (MVA-HCV in chronic hepatitis c). Mostly vaccine acting on inflammation.

1
Asset
Furthest stage
Phase 1
2
Trials
0
Signals

Pipeline

1

  • MVA-HCV

    Modified vaccinia Ankara viral vector expressing hepatitis C virus antigens to elicit immune response.

    Phase 1, Vaccine, Inflammation, chronic hepatitis c

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

1

In the full profile

  • Evidence behind the mechanisms2
  • Trials2
  • Similar companies6

Intelligence